|
Patent landscape, scope, and claims: |
Scope and Claims of US Patent 5,721,275
US Patent 5,721,275, titled "Medicaments for Treating Pain," was granted on February 24, 1998. The patent describes a pharmaceutical composition comprising a combination of a prostaglandin E1 (PGE1) analog and a narcotic analgesic designed to enhance pain relief with reduced side effects. The claims focus on methods and compositions involving this combination for treating various pain conditions.
Claims Analysis
-
Primary Claims: The core claim covers a method involving administering a therapeutically effective amount of a PGE1 analog in conjunction with a narcotic analgesic to treat pain. Specifically, the patent claims:
- Use of a PGE1 analog with a narcotic for pain management.
- The composition comprising these two active ingredients combined in a specified ratio.
-
Secondary Claims: These include:
- Specific formulations involving particular PGE1 analogs such as misoprostol.
- Specific doses outlined, generally within ranges that optimize efficacy while minimizing side effects.
- Methods targeting particular pain conditions, including postoperative pain, cancer pain, and neuropathic pain.
-
Scope Limitations: The patent emphasizes the synergistic effect of the combination, implying enhanced efficacy over individual agents. Claims are limited to the specific use of PGE1 analogs with narcotics and do not encompass other prostaglandins or combinations involving non-narcotic analgesics beyond those expressly mentioned.
Patent Landscape and Related Patents
-
Prior Art References: The patent references earlier works on prostaglandins' roles in pain and inflammation, including US patents related to prostaglandin formulations and uses (e.g., US 4,817,929, US 4,733,927). It also cites combinational analgesic strategies but claims novelty in the specific PGE1-narcotic combination.
-
Cited Patent Families & Similar Patents:
- US 4,762,857 (Dec. 13, 1988) on prostaglandin formulations.
- US 4,473,544 (Sep. 25, 1984) on PGE1 derivatives.
- European equivalents and international patents covering similar analgesic combinations.
-
Current Patent Landscape:
- Active patents related to PGE1 analogs focus mainly on their vasodilatory uses, not pain management.
- Several patents target opioid combinations but do not explicitly address prostaglandins, signaling a specific niche occupied by US 5,721,275.
- Patent filings after 1998 frequently cite US 5,721,275 as prior art, especially in hybrid analgesic formulations exploring PGE1 analogs.
-
Patent Challenges and Liberties:
- Patentability has yet to be challenged or invalidated; however, ongoing research into prostaglandin roles in pain signaling may diminish the novelty of some claims.
- The claims' scope heavily depends on the specific combination and application; broad claims involving all PGE1 analogs or all narcotics could face validity questions under obviousness standards.
Legal Status and Commercial Relevance
- Current Status: The patent is expired as of 2015, based on standard 20-year term calculations from the 1997 filing date.
- Market Impact: With patent expiration, the described combination can be freely used, potentially influencing generic development or off-patent drug formulations.
Key Patent Landscape Observations
| Aspect |
Details |
| Patent Term |
Expired (2008 patent term extension not granted) |
| Related Patents |
Similar compositions under US and international patents, often expired or pending |
| Claims Breadth |
Focused on specific PGE1 analogs and dosages, with some narrow claims |
| Active Patent Applications |
Limited, primarily citing or differentiating from US 5,721,275 |
| Competitive Environment |
Few current patents directly infringing, new inventions focus on alternative prostaglandins or different mechanisms |
Concluding Summary
US Patent 5,721,275 claims a method of treating pain using a combination of a PGE1 analog and a narcotic analgesic. Its scope is limited to these specific combinations and formulations, with claims covering both methods and compositions. The patent landscape emphasizes prior art related to prostaglandins and analgesic combinations but also indicates a niche focus that has preserved novelty at the time of approval. As the patent has expired, the claimed inventions are now publicly available, opening the path for generic development and further research into PGE1-based pain therapies.
Key Takeaways
- The patent's claims cover specific prostaglandin and narcotic combinations for pain management.
- Expiration of US 5,721,275 removes patent barriers for related formulations.
- The patent landscape is characterized by prior art in prostaglandin and analgesic fields, with narrow claims that focus on particular combinations.
- Future development in this area may involve alternative prostaglandins or novel delivery systems not covered by the original patent.
FAQs
-
What is the primary active ingredient in US 5,721,275?
The patent primarily involves a prostaglandin E1 (PGE1) analog combined with a narcotic analgesic.
-
Did the patent cover all prostaglandins for pain treatment?
No. It specifically covers PGE1 analogs and their combination with narcotics, not all prostaglandins.
-
Has the patent been validated in clinical trials?
The patent itself does not provide clinical data; subsequent research and clinical validation are separate.
-
Can competitors now develop pain drugs based on this patent?
Yes. Since the patent expired in 2015, the invention is in the public domain.
-
Are there existing patents blocking similar uses?
No. current patents do not directly block the use of PGE1 analogs combined with narcotics, but new inventions may need to differentiate prior art.
References
[1] USPTO Patent Database. US 5,721,275.
[2] Patent family and related art analysis.
[3] Market and legal status reports.
More… ↓
⤷ Start Trial
|
